DZ3388A1 - Analogues de peptide 1 du type glucagon - Google Patents

Analogues de peptide 1 du type glucagon

Info

Publication number
DZ3388A1
DZ3388A1 DZ013388A DZ013388A DZ3388A1 DZ 3388 A1 DZ3388 A1 DZ 3388A1 DZ 013388 A DZ013388 A DZ 013388A DZ 013388 A DZ013388 A DZ 013388A DZ 3388 A1 DZ3388 A1 DZ 3388A1
Authority
DZ
Algeria
Prior art keywords
analogs
glucagon peptide
glucagon
peptide
Prior art date
Application number
DZ013388A
Other languages
English (en)
French (fr)
Inventor
Wolfgang Glaesner
Rohn Lee Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ3388A1 publication Critical patent/DZ3388A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ013388A 2000-06-16 2001-06-01 Analogues de peptide 1 du type glucagon DZ3388A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21217100P 2000-06-16 2000-06-16
US24034900P 2000-10-13 2000-10-13
PCT/US2001/016474 WO2001098331A2 (en) 2000-06-16 2001-06-01 Glucagon-like peptide-1 analogs

Publications (1)

Publication Number Publication Date
DZ3388A1 true DZ3388A1 (fr) 2001-12-27

Family

ID=26906843

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013388A DZ3388A1 (fr) 2000-06-16 2001-06-01 Analogues de peptide 1 du type glucagon

Country Status (33)

Country Link
US (2) US7084243B2 (ru)
EP (2) EP1294757B1 (ru)
JP (1) JP4716641B2 (ru)
KR (1) KR100847615B1 (ru)
CN (1) CN100469791C (ru)
AR (1) AR031701A1 (ru)
AT (2) ATE424413T1 (ru)
AU (2) AU6479101A (ru)
BR (1) BR0111562A (ru)
CA (1) CA2412004C (ru)
CY (2) CY1105917T1 (ru)
CZ (1) CZ304002B6 (ru)
DE (2) DE60137876D1 (ru)
DK (2) DK1294757T3 (ru)
DZ (1) DZ3388A1 (ru)
EA (1) EA008837B1 (ru)
EG (1) EG24755A (ru)
ES (2) ES2275685T3 (ru)
HK (1) HK1055121A1 (ru)
HR (1) HRP20020996B1 (ru)
HU (2) HU229108B1 (ru)
IL (2) IL153453A0 (ru)
MX (1) MXPA02012203A (ru)
MY (1) MY137350A (ru)
NO (1) NO330686B1 (ru)
NZ (1) NZ522330A (ru)
PE (1) PE20011363A1 (ru)
PL (1) PL206302B1 (ru)
PT (2) PT1695983E (ru)
SI (1) SI1695983T1 (ru)
SK (1) SK287757B6 (ru)
TW (1) TWI321134B (ru)
WO (1) WO2001098331A2 (ru)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
PL206302B1 (pl) * 2000-06-16 2010-07-30 Elli Lilly And Companyelli Lilly And Company Związek GLP-1
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1572892A4 (en) * 2001-10-18 2007-08-22 Bristol Myers Squibb Co HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
WO2003072195A2 (en) * 2002-02-20 2003-09-04 Eli Lilly And Company Method for administering glp-1 molecules
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003103572A2 (en) * 2002-06-04 2003-12-18 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050059605A1 (en) * 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
JP2007524579A (ja) * 2003-02-19 2007-08-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
ES2383752T3 (es) 2003-05-15 2012-06-26 Trustees Of Tufts College Analogos estables de GLP-1
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
BRPI0410972C1 (pt) * 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP2368909A1 (en) 2003-06-12 2011-09-28 Eli Lilly and Company GLP-1 analog fusion proteins
MXPA06005581A (es) 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
JP2007536214A (ja) * 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
TWI353250B (en) * 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
SI2298901T2 (sl) 2004-04-30 2017-08-31 Dow Agrosciences Llc Novi geni z rezistenco na herbicide
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
JP4965446B2 (ja) * 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
EP1817048B1 (en) 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
ES2541633T3 (es) 2005-01-14 2015-07-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendinas modificadas y usos de las mismas
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006098524A1 (ja) * 2005-03-18 2006-09-21 Ajinomoto Co., Inc. ストレスによる腸疾患の予防・治療剤
BRPI0609676A2 (pt) * 2005-05-13 2011-10-18 Lilly Co Eli composto de glp-1 peguilado,e, uso do mesmo
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
BRPI0618025B1 (pt) 2005-10-28 2016-12-27 Dow Agrosciences Llc método para controlar ervas daninhas em uma área, polinucleotídeo isolado, célula de planta e planta resistente a herbicida
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008063203A2 (en) * 2006-01-27 2008-05-29 Whitehead Institute For Biomedical Research Compositions and methods for efficient gene silencing in plants
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
WO2008005527A2 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
AU2007275294A1 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
EP2363112B8 (en) 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
KR100851560B1 (ko) * 2006-12-27 2008-08-11 고려대학교 산학협력단 새로운 글루카곤 유사 펩타이드-1 (ｇｌｐ-1) 작용제 및 그용도
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CN101041693B (zh) * 2007-02-06 2011-08-17 珠海联邦制药股份有限公司 一种降血糖多肽及其应用
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2157967B1 (en) * 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
US8464239B2 (en) * 2007-06-11 2013-06-11 Red Hat, Inc. Real-time installation and/or configuration assistant
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
CA2703338A1 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
CN101337989B (zh) * 2008-08-28 2012-10-24 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
ES2614427T3 (es) 2008-11-07 2017-05-31 The General Hospital Corporation Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20200028501A (ko) 2009-06-12 2020-03-16 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
CA2767792A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
DK3311828T3 (da) * 2009-08-14 2021-06-28 Phasebio Pharmaceuticals Inc Modificerede vasoaktive tarmpeptider
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
RU2012122162A (ru) * 2009-10-30 2013-12-10 Глитек,Инк. Гликолизированная форма аналога антигенного glp-1
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US9445992B2 (en) 2009-11-25 2016-09-20 Arisgen Sa Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
BR112012028704A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
SG185604A1 (en) * 2010-05-17 2012-12-28 Zhejiang Beta Pharma Inc Novel glucagon like peptide analogs, composition, and method of use
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
MX2013006304A (es) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
CN102180963B (zh) * 2011-04-22 2014-06-25 中国药科大学 胰高血糖素样肽-1(glp-1)类似物及其应用
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN103087178A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087176A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087179A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087177A (zh) * 2012-11-30 2013-05-08 中国药科大学 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087175A (zh) * 2012-11-30 2013-05-08 中国药科大学 新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
CN104262481B (zh) * 2013-08-09 2018-02-09 天津药物研究院有限公司 一种侧链修饰的长效glp‑1类似物的制备方法及其应用
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
BR112017008160A8 (pt) * 2014-10-24 2023-04-11 Merck Sharp & Dohme Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
CA3010265A1 (en) * 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
RS65380B1 (sr) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 kompozicije i njihova upotreba
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
PL4122954T3 (pl) 2018-04-05 2024-08-12 Sun Pharmaceutical Industries Limited Nowe analogi GLP-1
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso
KR20210081376A (ko) 2018-10-30 2021-07-01 지아닝 리우 Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
UA65549C2 (ru) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
JP2001513512A (ja) 1997-08-08 2001-09-04 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンディン作動剤化合物
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
DE69911975T2 (de) * 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
PL206302B1 (pl) * 2000-06-16 2010-07-30 Elli Lilly And Companyelli Lilly And Company Związek GLP-1
US7271149B2 (en) * 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
EP2461836A4 (en) * 2009-08-07 2013-04-17 Perry Felix METHOD AND APPARATUS FOR SURFACE AND SURFACE DISINFECTION OF FOODSTUFFS IN A COOKING APPARATUS USING ULTRAVIOLET LIGHT

Also Published As

Publication number Publication date
NZ522330A (en) 2004-11-26
HK1055121A1 (en) 2003-12-24
EP1294757A2 (en) 2003-03-26
CZ304002B6 (cs) 2013-08-14
HUP0301212A3 (en) 2004-09-28
SK287757B6 (sk) 2011-08-04
EP1695983B1 (en) 2009-03-04
JP4716641B2 (ja) 2011-07-06
DE60137876D1 (de) 2009-04-16
NO20025949L (no) 2002-12-11
PL206302B1 (pl) 2010-07-30
JP2004501162A (ja) 2004-01-15
NO330686B1 (no) 2011-06-06
US20060263849A1 (en) 2006-11-23
KR100847615B1 (ko) 2008-07-21
AU6479101A (en) 2002-01-02
US7498308B2 (en) 2009-03-03
EA200300026A1 (ru) 2003-04-24
PT1294757E (pt) 2007-02-28
NO20025949D0 (no) 2002-12-11
US7084243B2 (en) 2006-08-01
CY1105917T1 (el) 2011-04-06
DE60124710T2 (de) 2007-09-13
DK1695983T3 (da) 2009-05-18
EA008837B1 (ru) 2007-08-31
DE60124710D1 (de) 2007-01-04
CA2412004A1 (en) 2001-12-27
MXPA02012203A (es) 2003-06-06
WO2001098331A3 (en) 2003-01-03
SI1695983T1 (sl) 2009-08-31
CA2412004C (en) 2010-12-21
BR0111562A (pt) 2003-04-15
HRP20020996B1 (en) 2011-09-30
PL360406A1 (en) 2004-09-06
CN100469791C (zh) 2009-03-18
AR031701A1 (es) 2003-10-01
IL153453A (en) 2009-11-18
WO2001098331A2 (en) 2001-12-27
US20030220243A1 (en) 2003-11-27
IL153453A0 (en) 2003-07-06
MY137350A (en) 2009-01-30
EP1294757B1 (en) 2006-11-22
EP1695983A2 (en) 2006-08-30
ES2275685T3 (es) 2007-06-16
HUP0301212A2 (hu) 2003-08-28
EP1695983A3 (en) 2007-02-21
CY1109061T1 (el) 2014-07-02
CZ20024088A3 (cs) 2003-05-14
ES2321439T3 (es) 2009-06-05
HRP20020996A2 (en) 2004-02-29
HU229108B1 (en) 2013-09-30
ATE424413T1 (de) 2009-03-15
PT1695983E (pt) 2009-05-05
DK1294757T3 (da) 2007-03-19
HU229208B1 (en) 2013-09-30
CN1468258A (zh) 2004-01-14
EG24755A (en) 2010-07-26
KR20030009537A (ko) 2003-01-29
SK17782002A3 (sk) 2003-07-01
ATE346093T1 (de) 2006-12-15
PE20011363A1 (es) 2002-01-15
TWI321134B (en) 2010-03-01
AU2001264791B2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
DZ3388A1 (fr) Analogues de peptide 1 du type glucagon
FR12C0041I2 (fr) Analogues de somatostatine
NO20032101D0 (no) Apoliprotein analoger
NO995568L (no) Paratyroidhormon peptidanaloger
DE69941708D1 (de) Pacap-peptidanaloga
EE03832B1 (et) Heptapeptiidanaloogid
DK1124779T3 (da) D-vitaminanaloge forbindelser
NO20030916D0 (no) Selektive cykliske peptider
NO982097L (no) Peptider
NO982098D0 (no) Peptider
DK1292612T3 (da) Glycopeptidphosphonatderivater
NO20023367L (no) Glyburide-preparat
DK1401863T3 (da) Kimære somatostatin-dopamin-analoge
FI20000086A (fi) Järjestely ohjainsauvan yhteydessä
DE60139339D1 (de) Stabilisierte interferonzusammensetzungen
FR2813080B1 (fr) Peptides anti-heparine
NO20006320D0 (no) Cykliske somatostatin-analoger
DE60108200D1 (de) Geteiltes Webblatt
NO20032913D0 (no) Neurotrofiske tacrolimusanaloger
NO20032963L (no) Peptidforbindelser
IL150458A0 (en) Novel haptotactic peptides
DK1137667T3 (da) GLP-1-analoger
EP1312612A4 (en) CYCLIC PEPTIDE DERIVATIVE
FI20010860A0 (fi) Projisointipinta
SE0003187D0 (sv) Novel enkephalin analogues